Multiple myeloma: Current and future management in the aging population

Multiple myeloma (MM) is a plasma cell dyscrasia that accounts for 15% approximately of all hematological malignancies. The median age at diagnosis is 70 years, and about 34-40% of patients with MM are older than 75 years [1,2]. Outcomes and overall survival have improved considerably as novel therapeutics continue to evolve with immunotherapy, targeted combination treatments, and routine incorporation of autologous stem cell transplantation (ASCT) in clinical practice [3]. In the modern era, MM patients younger than age 65 have a 10  year improved survival rate (9.6% vs.
Source: Maturitas - Category: Primary Care Authors: Source Type: research